Astrazeneca's Ultomiris Misses Primary Goal in Late-Stage Rare-Disease Trial
MT Newswires Live
Jul 27
Astrazeneca's (AZN) Ultomiris missed the primary endpoint in a phase 3 trial in patients with thrombotic microangiopathy after stem-cell transplant, the company said Monday.
The therapy failed to achieve statistical significance for event-free survival at 26 weeks in adult and adolescent patients, though the study showed a trend toward benefit versus placebo, the company said.
Astrazeneca said discussions with regulators are ongoing regarding interpretation of the data.
In a separate phase 3 trial in pediatric patients, Ultomiris delivered clinically meaningful overall survival of 87.2% at 26 weeks at 73.4% at 52 weeks, and the company said it will advance regulatory filings for use in children.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.